continuation sheet

## Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months ended December 31, 2020

(Rs. In Lakhs, unless otherwise stated)

		Quarter ended			Nine Months ended		Year ended
Sr. No.	Particulars	31-12-2020 30-09-2020 31-12-2019			31-12-2020 31-12-2019		31-03-2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
1	Revenue from Operations	993.28	813.66	1315.91	2409.32	4163.63	5561.43
11	Other Income	0.11		0.15	0.58	0.71	9.26
III	Total Revenue (I + II)	993,39	813.66	1316.06	2409.90	4164.34	5570.69
IV	Expenses:		0.000	101000	2103130	1101131	3370.03
	(a) Cost of Material Consumed	374.93	375.79	562.02	1078.29	1780.76	2455.26
	(b) Purchase of Stock-in-Trade	-	-	-	1070.23	28.80	37.02
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	(220.63)	(288.37)	(132.04)	(782.20)	(217.58)	(63.32
	(d) Employee Benefits Expenses	282.08	238.87	277.03	745.01	768.03	1067.37
	(e) Finance Cost	65.82	44.98	26.61	135.93	85.11	218.32
	(f) Depreciation and Amortisation Expenses	35.97	43.79	19.35	118.12	51.64	155.39
	(g) Other Expenses	392.20	345.85	504.42	977.65	1478.07	1485.15
	Total Expenses (IV)	930.37	760.91	1257.39	2272.79	3974.83	5355.19
V	Profit / (Loss) before Exceptional items and Tax (III - IV)	63.02	52.74	58,68	137.11	189.51	
VI	Exceptional Items	03,02	52.74	20.00	137,11	102.01	215.50
VII	Profit / (Loss) Before Tax (V - VI)	63.02	52.74	58.68	137.11	100.51	315.50
VIII	Tax Expense :	63.02	52.74	50.00	13/.11	189.51	215.50
	(1) Current Tax	30.90	12.71	15.67	24.54	47.70	74.50
	(2) Deferred tax	20.80	13.71	15.67	34.51	47.70	71.58
	Total Tax Expenses	- 20.00	- 42.74	45.67	- 24.54	- 47.70	14.33
IX	Profit / (Loss) for the period from Continuing Operations (VII -VIII)	20.80 42.22	13.71 39.03	15.67	34.51	47.70	85.91
X	Profit / (Loss) from Discontinued Operations			43.01	102.60	141.81	129.59
XI	Tax expenses of Discontinued Operations	-	-	-	-	-	-
XII	1	-	-	-	-	-	-
XIII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	-	-	-	-	-	-
XIV	Profit / (Loss) for the period (IX+XII)	42.22	39.03	43.01	102.60	141.81	129.59
	Other Comprehensive Income A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-		
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss			_	-		
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	42.22	39.03	43.01	102.60	141.81	129.59
XVI	Details of Equity share capital		`				
A11	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	264.92	364.93	264.02	204.02
	Face value of Equity Share Capital	10.00	10,00	364.83	364.83	364.83	364.83
XVII	Earnings Per Equity Share (for Continuing operation) :	10.00	10.00	10.00	10.00	10.00	10,00
	(a) Basic	1.45	1.07	4.10	2.21	2.00	0.55
		1.16	1.07	1.18	2.81	3.89	3.55
	(b) Diluted	1.16	1.07	1.18	2.81	3.89	3.55
XVIII	Earnings Per equity share (for Discontinued operation) :						
	(a) Basic	-	-	-	-	-	-
VVIIV	(b) Diluted	-	-	-	-	-	-
XVIX	Earnings Per Equity Share (for Discontinued & Continuing operation) :						
	(a) Basic	1.16	1.07	1.18	2.81	3.89	3.55
	(b) Diluted	1.16	1.07	1.18	2.81	3.89	3.55

## Notes

- 1]. The Company has one reportable business segment "Medical Devices" and the above Financial Results for the Quarter and Nine Months ended December 31, 2020 in respect of CENTENIAL SURGICAL SUTURE LTD., ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 28, 2021. The above results have been subjected to limited review by the statutory auditors of the Company and the report of the statutory auditors is unqualified.
- 2]. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Prior period / year figures have been reclassified wherever required to conform to the classification of the current period / year, and are available on www.bseindia.com & on www.centenialindia.com.
- 3]. In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption. The company has considered internal and external information while finalising various estimates in relation to its financial results captions upto the date of approval of the financial results by the Board of Directors and the company will continue to closely monitor any material changes to future economic conditions.

Place: Mumbai, Maharashtra Date: January 28, 2021



for and on behalf of the Board of Directors of ENTENIAL SURGICAL SUTURE LTD.

Vijay MAJREKAR Managing Director ~ DIN: 00804808